Team:Slovenia/Idea

From 2012.igem.org

(Difference between revisions)
 
(31 intermediate revisions not shown)
Line 2: Line 2:
<head>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
 +
 +
<!-- back to top -->
 +
<div style="position:fixed; bottom:45px; right:30px; width:100px; height:66px; background-color:transparent;">
 +
<a href="#topofthepage">
 +
<table style="background-color:transparent;" onclick="window.location = '#topofthepage'" class="invisible" style="height:100%;">
 +
<tr class="invisible" style="background-color:transparent;">
 +
<td class="invisible" style="background-color:transparent;" valign="center">
 +
<img width="100px" src ="https://static.igem.org/mediawiki/2012/1/14/Svn12_hp_btt.png"></img>
 +
</td></tr></table>
 +
</a>
 +
</div>
<style type="text/css">
<style type="text/css">
Line 13: Line 24:
-
p {line-height:1.5em; margin:0 0 15px; text-align:left;}
+
p {line-height:1.5em; margin:0 0 15px; text-align:justify;}
h2 {font-size:1.8em; font-weight:400; margin:0 0 12px;}
h2 {font-size:1.8em; font-weight:400; margin:0 0 12px;}
Line 182: Line 193:
 +
p.inliner{text-align:justify; }
 +
img.inliner{width:100%; border-width:0px;}
 +
table.inliner{border-width:0px; float:right; width:60%; margin-bottom:15px; margin-left:15 px; margin-right:15 px; padding-left:15px; }
 +
td.inliner, th.normal { border-width:0px;}
 +
thead.inliner{}
 +
tbody .inliner{}
 +
 +
/* CSS navigation menu (blue) */
/* CSS navigation menu (blue) */
/* CSS navigation menu (blue) */
#cssmenu{ height:37px; display:block; padding:0; margin:0;  border:1px solid; border-radius:0px; }  
#cssmenu{ height:37px; display:block; padding:0; margin:0;  border:1px solid; border-radius:0px; }  
Line 201: Line 220:
#cssmenu ul li > ul li{display:block; list-style:inside none; padding:0; margin:0; position:relative;}  
#cssmenu ul li > ul li{display:block; list-style:inside none; padding:0; margin:0; position:relative;}  
#cssmenu ul li > ul li a{ outline:none; display:block; position:relative; margin:0; padding:8px 20px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }  
#cssmenu ul li > ul li a{ outline:none; display:block; position:relative; margin:0; padding:8px 20px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }  
 +
#cssmenu ul li > ul li a table tr td span{ outline:none; display:block; position:relative; margin:0; padding:0px 0px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); }
#cssmenu, #cssmenu > ul > li > ul > li a:hover
#cssmenu, #cssmenu > ul > li > ul > li a:hover
{ background:#043A6B;  
{ background:#043A6B;  
Line 216: Line 236:
#cssmenu > ul > li > a:hover{background:#0C5DA5;}  
#cssmenu > ul > li > a:hover{background:#0C5DA5;}  
/* end CSS navigation menu (blue) */
/* end CSS navigation menu (blue) */
 +
 +
/*new table start*/
 +
table.newtable {background-color:transparent;}
 +
td.newtable, th.newtable {background-color:transparent;}
 +
thead.newtable{ }
 +
tbody .newtable{}
 +
/*new table start*/
Line 292: Line 319:
<body>
<body>
-
 
+
<!-- pod body -->
 +
<a name="topofthepage" style="background-color:transparent;"></a>
<div id="banner">
<div id="banner">
</div>
</div>
Line 306: Line 334:
<li class='has-sub '><a href='https://2012.igem.org/Team:Slovenia/Idea'><span>Idea</span></a>
<li class='has-sub '><a href='https://2012.igem.org/Team:Slovenia/Idea'><span>Idea</span></a>
  <ul>
  <ul>
-
<li><a href='https://2012.igem.org/Team:Slovenia/Idea'><span>Biological therapy</span></a></li>
+
<li><a href='https://2012.igem.org/Team:Slovenia/IdeaBioTherapy'><span>Biological therapy</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/IdeaChallenge'><span>Challenge</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/IdeaChallenge'><span>Challenge</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/IdeaSolution'><span>Solution</span></a></li>
+
<li><a href='https://2012.igem.org/Team:Slovenia/Idea'><span>Solution</span></a></li>
  </ul>
  </ul>
</li>
</li>
Line 316: Line 344:
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators'><span>Designed TAL regulators</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators'><span>Designed TAL regulators</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>  
-
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>  
+
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch';" class="newtable"><tr class="newtable"><td class="newtable"><span>Positive feedback loop switch</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 +
    <li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchControls'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchControls';" class="newtable"><tr class="newtable"><td class="newtable"><span>Controls</span></td><td class="newtable"><img style="margin-right:-81px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>  
  </ul>
  </ul>
</li>
</li>
Line 324: Line 353:
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsEscapeTag'><span>Escape tag</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsEscapeTag'><span>Escape tag</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsTermination'><span>Termination</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsTermination'><span>Termination</span></a></li>  
-
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation'><span>Microcapsule degradation</span></a></li>  
+
    <li><a href="https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation"><table  onclick="window.location = 'https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation';" class="newtable"><tr class="newtable"><td class="newtable"><span>Microcapsule degradation</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>  
  </ul>
  </ul>
</li>
</li>
Line 332: Line 361:
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationHepatitisC'><span>Hepatitis C</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationHepatitisC'><span>Hepatitis C</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationIschaemicHeartDisease'><span>Ischaemic heart disease</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationIschaemicHeartDisease'><span>Ischaemic heart disease</span></a></li>  
 +
    <li><a href='https://2012.igem.org/Team:Slovenia/ImplementationImpact'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ImplementationImpact';" class="newtable"><tr class="newtable"><td class="newtable"><span>Impact</span></td><td class="newtable"><img style="margin-right:-86px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 
 
  </ul>
  </ul>
Line 339: Line 369:
  <ul>
  <ul>
<li><a href='https://2012.igem.org/Team:Slovenia/Modeling'><span>Overview</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/Modeling'><span>Overview</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingPK'><span>Pharmacokinetics</span></a></li>
+
    <li><a href='https://2012.igem.org/Team:Slovenia/ModelingPK'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingPK';" class="newtable"><tr class="newtable"><td class="newtable"><span>Pharmacokinetics</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMethods'><span>Modeling methods</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMethods'><span>Modeling methods</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel'><span>Quantitative and stability model</span></a></li>
+
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel';" class="newtable"><tr class="newtable"><td class="newtable"><span>Experimental model</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
 +
    <li><a href='https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations';" class="newtable"><tr class="newtable"><td class="newtable"><span>Interactive simulations</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
  </ul>
  </ul>
</li>
</li>
Line 354: Line 385:
  <ul>
  <ul>
<li><a href='https://2012.igem.org/Team:Slovenia/Notebook'><span>Experimental methods</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/Notebook'><span>Experimental methods</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/NotebookLablog'><span>Lablog</span></a></li>
+
    <li><a href='https://2012.igem.org/Team:Slovenia/NotebookLablog'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/NotebookLablog';" class="newtable"><tr class="newtable"><td class="newtable"><span>Lablog</span></td><td class="newtable"><img style="margin-right:-90px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/NotebookLabSafety'><span>Lab safety</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/NotebookLabSafety'><span>Lab safety</span></a></li>  
  </ul>
  </ul>
Line 363: Line 394:
<li><a href='https://2012.igem.org/Team:Slovenia/Society'><span>Human practice</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/Society'><span>Human practice</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyScientists'><span>Scientists</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyScientists'><span>Scientists</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyMedicalDoctors'><span>Medical doctors</span></a></li>
+
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyMedicalDoctors'><span>Physicians</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyEthics'><span>Ethics, safety and regulations</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyEthics'><span>Ethics, safety and regulations</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyPatients'><span>Patients</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyPatients'><span>Patients</span></a></li>
-
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyMedia'><span>Media and general public</span></a></li>  
+
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyMedia'><span>Journalists and general public</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyOutreach'><span>Outreach</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyOutreach'><span>Outreach</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyQuestionnaire'><span>Questionnaire</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/SocietyQuestionnaire'><span>Questionnaire</span></a></li>  
Line 377: Line 408:
<li><a href='https://2012.igem.org/Team:Slovenia/Team'><span>Team members</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/Team'><span>Team members</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TeamAttributions'><span>Attributions</span></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TeamAttributions'><span>Attributions</span></a></li>
 +
<li><a href='https://2012.igem.org/Team:Slovenia/TeamCollaborations'><table  onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TeamCollaborations';" class="newtable"><tr class="newtable"><td class="newtable"><span>Collaborations</span></td><td class="newtable"><img style="margin-right:-20px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li>
<li><a href='https://2012.igem.org/Team:Slovenia/TeamGallery'><span>Gallery</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TeamGallery'><span>Gallery</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TeamSponsors'><span>Sponsors</span></a></li>  
<li><a href='https://2012.igem.org/Team:Slovenia/TeamSponsors'><span>Sponsors</span></a></li>  
Line 384: Line 416:
</div>
</div>
<!-- end main menu -->
<!-- end main menu -->
 +
</div> <!-- end menu -->
</div> <!-- end menu -->
Line 389: Line 422:
<div id="main">
<div id="main">
<br/>
<br/>
 +
 +
<!-- dummy link na bannerju -->
 +
<a href="https://2012.igem.org/Main_Page">
 +
<div id="dummy" style="background-color:transparent; position:absolute; left:870px; top:25px; width:115px; height:80px; z-index:100; opacity:0.0;">
 +
</div>
 +
</a>
 +
 +
 +
 +
<h1>Idea</h1>
<h1>Idea</h1>
-
<p>
+
<p>For this year's Team Slovenia iGEM project we wanted to <b>exploit the advantages of synthetic biology</b> for an <b>advanced medical therapy</b> which could overcome some of the difficulties connected to current application of biopharmaceuticals. </p>
-
For this year's Team Slovenia iGEM project we wanted to <b>exploit the advantages of synthetic biology for an alternative biological medical therapy</b> which could overcome some of the difficulties connected to current biopharmaceuticals.
+
-
</p>
+
-
<p>
+
<p>Each disease and its corresponding therapy is a story of its own, but we sought to design a <b>synthetic biological platform for drug application</b> that could be tailored to the treatment of different diseases and would <b>include safety components</b> that would guarantee safety regardless of the specific therapeutic application. </p>
-
Each disease and its corresponding therapy is a story of its own, but we sought to design a synthetic biological solution for drug application that could be used to treat different diseases and include safety components that could be useful in different therapeutic applications.
+
-
</p>
+
-
<p>
+
<p>Our solution was to engineer mammalian cells, so that they would produce and deliver biological drugs inside the organism, as if the drugs were produced by the host cells themselves. The key to any advanced therapy based on this idea is the ability to exert a high level of control on the state of the cells. We have to incorporate <b>genetic switches</b> into the engineered cells allowing controlled production of one or several desired therapeutics, depending on the stage of the disease. We concluded that the engineered cells should be incorporated into <b>microcapsules, which is a safe and well-tested technology that</b> may be implanted into the affected tissue to ensure an immune-privileged environment for the therapeutic cells. The semi-permeable capsule allows a flux of nutrients and effector molecules through the capsule’s pores but prevents cell escape and dissemination throughout the body. For the unlikely case of cells escaping from capsules, we sought to design a safety tag ensuring destruction of cells outside microcapsules by the patient's immune system. This form of therapy should also have the ability to be terminated at any given time by an outside signal that would trigger <b>microcapsule degradation</b> and <b>therapeutic cell apoptosis</b> in which case no traces of the exogenous material should remain in the tissue. </p>
-
Our solution was to engineer mammalian cells, so that they will produce and deliver biological drugs inside the organism, as if the drugs were produced by the host cells themselves. Within the engineered cells, we planned to incorporate <b>genetic switches</b> allowing controlled production of one or several desired therapeutics, depending on the stage of the disease. The engineered cells are incorporated in <b>microcapsules</b> that may be implanted into the affected tissue to ensure an immune-privileged environment for the therapeutic cells. The semi-permeable capsules allow the flux of nutrients and effector molecules through the capsule’s pores but prevent cell escape and dissemination throughout the body. For the unlikely case of cells escaping capsules, we designed a safety tag ensuring destruction of cells outside microcapsules by the patient's immune system. This form of therapy may be terminated at any given time by an outside signal inducing <b>microcapsule degradation</b> and <b>therapeutic cell apoptosis</b> in which case no traces of the exogenous material should remain in the tissue.
+
-
</p>
+
Line 409: Line 446:
<b style="text-size:110%;">The main features of our proposed therapeutic device:</b>
<b style="text-size:110%;">The main features of our proposed therapeutic device:</b>
<ol>
<ol>
-
<li>Production of <b>therapeutic proteins within the organism</b> (no need for purification)</li>
+
<li>Production of <b>therapeutic proteins within the organism</b> (no need for purification).</li>
-
<li>Use of cell <b>microencapsulation</b> to allow application of the <b>same type of engineered cells</b> for all patients to <b>avoid immune response, increase the reliability and predictability of the response and decrease cost</b></li>
+
<li><b>Cell microencapsulation</b> into alginate or another biocompatible carrier to allow application of the <b>same type of validated engineered cells</b> for all patients, to <b>avoid immune response, increase the reliability and predictability of the therapy and decrease the cost by mass production instead of individualized therapeutic engineering of patient's own cells.</b> Microencapsulation also allows <b>localized release of therapeutic proteins</b> into the affected tissue, which can <b>decrease the systemic side effects. </b></li>
-
<li>Microencapsulation of cells allows <b>localized release of therapeutic proteins</b> in the affected tissue, which can <b>decrease the systemic side effects</b></li>
+
<li><b>Regulated production of different therapeutic proteins appropriate for different stages of disease. </b> Switching between the different states of therapeutic cells should be possible by a short pulse of an inducer that can be applied to patients orally. This signal should trigger the flip of the bistable switch, which should remain stable in the new state even in the absence of the inducer. </li>
-
<li>Regulation of <b>production of different therapeutic proteins appropriate for different stages of therapy</b>. Switching between the different states of therapeutic cells is possible by a short pulse of the inducer, that can be applied to patients orally</li>
+
<li>For an advanced therapy we would <b>need several switches in a single cell</b>, which has not yet been demonstrated.
-
<li>Introduction of an <b>escape killer tag</b> for the <b>elimination of cells that may escape from microcapsules</b> through augmented targeting by natural killer cells</li>
+
<li>Introduction of an <b>escape tag</b> for the <b>elimination of cells that may escape from microcapsules</b> through augmented targeting by natural killer cells. </li>
-
<li>At the end of therapy the alginate <b>microcapsule shell</b> is degraded by a secretory alginate lyase followed by induced <b>apoptosis of the therapeutic cells</b></li>
+
<li>At the end of therapy the alginate <b>microcapsule shell</b> should be degraded by a secretory alginate lyase followed by induced <b>apoptosis of the therapeutic cells. </b></li>
 +
 
<ol>
<ol>
</td>
</td>
Line 421: Line 459:
<!-- /summary table -->
<!-- /summary table -->
-
<!-- figure 1 -->
+
 
 +
 
<p>
<p>
-
<table class="normal" style="width:50%;">
+
<!-- figure 1 -->
-
<tbody  class="normal">
+
<table class="inliner">
-
<tr class="normal"><td class="normal"><img src="https://static.igem.org/mediawiki/2012/f/ff/SVN12_microcapsule_therapy.jpg"/></td></tr>
+
<tbody  class="inliner">
-
<tr class="normal"><td class="normal"><b>Figure 1.</b> Microencapsulated engineered cells in synthetic biology for the production and delivery of biological therapeutics.</td></tr>
+
<tr class="inliner"><td class="inliner"><img src="https://static.igem.org/mediawiki/2012/e/eb/Svn12_idea_ao_2.png"/></td></tr>
 +
<tr class="inliner"><td class="inliner"><b>Figure 1.</b> Microencapsulated engineered cells for the production and delivery of biological therapeutics.</td></tr>
</tbody>
</tbody>
</table>
</table>
-
</p>
 
<!-- end figure 1-->
<!-- end figure 1-->
 +
<div style="text-align:justify;">
 +
<p>An important advantage of the microencapsulated cell approach is that the therapeutic protein can reach <b>therapeutic concentrations locally</b> in the affected tissue, while maintaining a low systemic concentration, thus <b>avoiding systemic side effects</b>, such as systemic  immunosuppression. Production of protein therapeutics by implanted microencapsulated cells also <b>eliminates the need for repeated invasive administrations of therapeutics</b>, which are typically applied by injections. Repeated application of therapeutics into the liver, brain or other complex tissues, where local delivery could be beneficial, is quite difficult. The usual obvious solution would be gene therapy, which has, despite its early promises, not delivered many successful clinical applications because of the problems of viral delivery and variable effectiveness caused by the random site of integration. We therefore aimed to develop an implantable cellular device for the local, regulated and safe delivery of therapeutic proteins. Long term survival of encapsulated cells beyond months may however be problematic with current technology and their efficiency of therapeutic production may decrease, although efficient therapy of diabetes and hemophilia using microencapsulated cells has been demonstrated in animals for more than 6months. Nevertheless we concluded that we should focus at least initially on the therapy of acute conditions. </p>
 +
</div>
 +
<div style="clear:both;"></div>
 +
 +
<!--
<p>
<p>
-
An important advantage of the microencapsulated cell approach is that the therapeutic protein can reach <b>the therapeutic local concentrations</b> in the affected tissue, while maintaining a low systemic concentration, thus <b>avoiding systemic side effects</b>, such as systemic immunosupression. Production of protein therapeutics by cells can also <b>eliminate the need for the repeated invasive administration of therapeutics</b>, which are typically applied by injections. Repeated application of therapeutics into the liver, brain or other complex tissues, where local delivery could be beneficial, is quite difficult. We aimed to develop an implantable cellular device for the local, regulated and safe delivery of therapeutic proteins. The usual obvious solution would be gene therapy, which has, despite its early promises, not delivered many successful clinical applications because of the problems of viral delivery and variable effectiveness due to the random site of integration. Long term survival of encapsulated cells beyond months may be problematic and their efficiency may decrease, therefore we should focus on the therapy of acute conditions.
 
-
</p>
 
-
 
-
 
<b>The desired properties of synthetic cellular devices for the next generation of cell-based therapies</b>
<b>The desired properties of synthetic cellular devices for the next generation of cell-based therapies</b>
<ul style="margin-left:15px;">
<ul style="margin-left:15px;">
-
<li>Control over the selection of different states of production of therapeutics or their combinations during different stages of therapy should be possible from the outside by a physician</li>
+
<li>Control over the selection of different states of therapeutic cells for production of different drug combinations during different stages of therapy should be possible from the outside by a physician</li>
<li>The ability to inactivate and destroy cells of the device at the end of the therapy, leaving as little remains as possible and elimination of any cells that might have escaped from microcapsules</li>
<li>The ability to inactivate and destroy cells of the device at the end of the therapy, leaving as little remains as possible and elimination of any cells that might have escaped from microcapsules</li>
</ul>
</ul>
 +
</p>
 +
-->
<br/>
<br/>
<h2>The synthetic biological components that needed to be developed</h2>
<h2>The synthetic biological components that needed to be developed</h2>
-
<h3>A Universal orthogonal bistable toggle switch for mammalian cells</h3>
+
<h3>Universal orthogonal bistable toggle switch for mammalian cells</h3>
-
<p>
+
 
-
The existing genetic switches used in mammalian cells are mainly based on the available prokaryotic transcriptional regulators, whose number is limited and whose properties may differ, hindering balanced switching. Our idea was to investigate the development of genetic switches based on the designed DNA-binding domains, such as TAL effectors that can achieve high orthogonality and support simultaneous introduction of several toggle switches  into mammalian cells. Although designed transcription factors have been created based on modular DNA binding proteins, such as zinc fingers and TAL effectors, to our best knowledge there have been no reports of genetic switches based on these types of elements. These devices would be extremely valuable since we could produce numerous orthogonal switches allowing development of complex functions and therapeutic devices.
+
-
<!-- figure 2 -->
 
<p>
<p>
-
<table class="normal">
+
<!-- figure 2 -->
-
<tbody  class="normal">
+
<table class="inliner" style="width:60%;">
-
<tr class="normal"><td class="normal"><img src="https://static.igem.org/mediawiki/2012/8/8b/SVN12_cell_multiple_switches.jpg"/></td></tr>
+
<tbody  class="inliner">
-
<tr class="normal"><td class="normal"><b>Figure 2.</b> Regulation of the several different states of therapeutic cells based on several orthogonal toggle switches.</tr>
+
<tr class="inliner"><td class="norinlinermal"><img src="https://static.igem.org/mediawiki/2012/d/d4/Svn12_idea_fig2_2.png" /></td></tr>
 +
<tr class="inliner"><td class="inliner"><b>Figure 2. </b> Regulation of the several different states of therapeutic cells based on several orthogonal toggle switches.</tr>
</tbody>
</tbody>
</table>
</table>
-
</p>
 
<!-- end figure 2 -->
<!-- end figure 2 -->
-
</p>
 
 +
<div style="text-align:justify;">
 +
The existing genetic switches used in mammalian cells are mainly based on the available prokaryotic transcriptional regulators, whose number is currently limited and whose properties may differ, hindering balanced switching. Our idea was to <b>investigate the development of orthogonal genetic switches based on designed DNA-binding domains</b>, such as <a href="https://2012.igem.org/Team:Slovenia/Parts#TALeffectors">TAL effectors</a> that could support simultaneous introduction of several toggle switches into mammalian cells. Although designed transcription factors have been created based on modular <a href="https://2012.igem.org/Team:Slovenia/Parts#TALs">DNA binding proteins</a>, such as zinc fingers and TAL effectors, to our best knowledge there have been no reports of genetic switches based on these types of elements. These devices would be extremely valuable since we could produce numerous orthogonal switches allowing development of complex control functions and therapeutic devices. </p>
 +
<div style:"clear:both;"></div>
 +
 +
<br/>
 +
<br/>
<br/>
<br/>
<h3>Safety mechanisms for therapy with microencapsulated cells</h3>
<h3>Safety mechanisms for therapy with microencapsulated cells</h3>
-
<p>
+
<p>For the safe therapeutic implementation of microencapsulated engineered cells in the organism we envisioned that we should be able to cease the therapy without having to physically remove the capsules. We therefore designed safety mechanisms that allow a complete removal of all exogenous material after the therapy has been completed. </p>
-
For the safe therapeutic implementation of microencapsulated engineered cells in the organism we envisioned that we should be able to cease the therapy without having to physically remove the capsules.
+
-
</p>
+
<!-- figure 3 -->
<!-- figure 3 -->
<p>
<p>
-
<table class="normal">
+
<table class="normal" style="border-width:0px;">
-
<tbody  class="normal">
+
<tbody  class="normal" style="border-width:0px;">
-
<tr class="normal"><td class="normal"><img width="50%" height="50%" src="https://static.igem.org/mediawiki/2012/3/3b/Svn12_apoptoza_overview.png"/></td></tr>
+
<tr class="normal" style="border-width:0px;"><td class="normal" style="border-width:0px;"><img style="border-width:0px;" src="https://static.igem.org/mediawiki/2012/3/3b/Svn12_apoptoza_overview.png" style="border-width:0px;"/></td></tr>
-
<tr class="normal"><td class="normal"><b>Figure 3.</b> Safety mechanisms that we planned to introduce for the application of microencapsulated engineered mammalian cells in therapy.
+
<tr class="normal" style="border-width:0px;"><td class="normal" style="border-width:0px;"><b>Figure 3.</b> Safety mechanisms that we planned to introduce for the application of microencapsulated engineered mammalian cells in therapy.  
-
 
+
</tr>
-
</tr>
+
</tbody>
</tbody>
</table>
</table>
Line 480: Line 523:
<!-- end figure 3 -->
<!-- end figure 3 -->
 +
<p><b> Microcapsule degradation</b> - Most of the microcapsules used in literature and therapy are composed of polymerized alginate that is biocompatible but cannot be degraded in mammalian tissues. Alginate lyase harvested from a marine microorganism effectively degrades alginate, so secretion of this enzyme from cells should degrade the capsules and allow their resorption by phagocytic cells. </p>
 +
 +
<p><b> Termination</b> - We should be able to inactivate the implanted cells at the end of the therapy or at any other stage if the therapy has to be terminated, regardless of the cause. We introduced a safety mechanism that would enable controlled induction of apoptosis of the implanted cells that is leak-free until the selected moment. Therefore we could inactivate therapeutic cells and enable their resorption without causing inflammation. </p>
 +
 +
<p><b> Escape tag</b> – This ensures that any cell that may have escaped from a microcapsule is eliminated by the immune system of the host organism. The escaped cells would most likely be recognized as foreign in any case but in order to provide maximal safety measures we decided to introduce an additional tag that would alert the natural killer cells of the host immune response. </p>
 +
<hr>
 +
<b>
 +
Next: <a href='https://2012.igem.org/Team:Slovenia/TheSwitch'>The switch >></a>
 +
</b>
</div>
</div>

Latest revision as of 20:44, 26 October 2012


Idea

For this year's Team Slovenia iGEM project we wanted to exploit the advantages of synthetic biology for an advanced medical therapy which could overcome some of the difficulties connected to current application of biopharmaceuticals.

Each disease and its corresponding therapy is a story of its own, but we sought to design a synthetic biological platform for drug application that could be tailored to the treatment of different diseases and would include safety components that would guarantee safety regardless of the specific therapeutic application.

Our solution was to engineer mammalian cells, so that they would produce and deliver biological drugs inside the organism, as if the drugs were produced by the host cells themselves. The key to any advanced therapy based on this idea is the ability to exert a high level of control on the state of the cells. We have to incorporate genetic switches into the engineered cells allowing controlled production of one or several desired therapeutics, depending on the stage of the disease. We concluded that the engineered cells should be incorporated into microcapsules, which is a safe and well-tested technology that may be implanted into the affected tissue to ensure an immune-privileged environment for the therapeutic cells. The semi-permeable capsule allows a flux of nutrients and effector molecules through the capsule’s pores but prevents cell escape and dissemination throughout the body. For the unlikely case of cells escaping from capsules, we sought to design a safety tag ensuring destruction of cells outside microcapsules by the patient's immune system. This form of therapy should also have the ability to be terminated at any given time by an outside signal that would trigger microcapsule degradation and therapeutic cell apoptosis in which case no traces of the exogenous material should remain in the tissue.

The main features of our proposed therapeutic device:
  1. Production of therapeutic proteins within the organism (no need for purification).
  2. Cell microencapsulation into alginate or another biocompatible carrier to allow application of the same type of validated engineered cells for all patients, to avoid immune response, increase the reliability and predictability of the therapy and decrease the cost by mass production instead of individualized therapeutic engineering of patient's own cells. Microencapsulation also allows localized release of therapeutic proteins into the affected tissue, which can decrease the systemic side effects.
  3. Regulated production of different therapeutic proteins appropriate for different stages of disease. Switching between the different states of therapeutic cells should be possible by a short pulse of an inducer that can be applied to patients orally. This signal should trigger the flip of the bistable switch, which should remain stable in the new state even in the absence of the inducer.
  4. For an advanced therapy we would need several switches in a single cell, which has not yet been demonstrated.
  5. Introduction of an escape tag for the elimination of cells that may escape from microcapsules through augmented targeting by natural killer cells.
  6. At the end of therapy the alginate microcapsule shell should be degraded by a secretory alginate lyase followed by induced apoptosis of the therapeutic cells.

Figure 1. Microencapsulated engineered cells for the production and delivery of biological therapeutics.

An important advantage of the microencapsulated cell approach is that the therapeutic protein can reach therapeutic concentrations locally in the affected tissue, while maintaining a low systemic concentration, thus avoiding systemic side effects, such as systemic immunosuppression. Production of protein therapeutics by implanted microencapsulated cells also eliminates the need for repeated invasive administrations of therapeutics, which are typically applied by injections. Repeated application of therapeutics into the liver, brain or other complex tissues, where local delivery could be beneficial, is quite difficult. The usual obvious solution would be gene therapy, which has, despite its early promises, not delivered many successful clinical applications because of the problems of viral delivery and variable effectiveness caused by the random site of integration. We therefore aimed to develop an implantable cellular device for the local, regulated and safe delivery of therapeutic proteins. Long term survival of encapsulated cells beyond months may however be problematic with current technology and their efficiency of therapeutic production may decrease, although efficient therapy of diabetes and hemophilia using microencapsulated cells has been demonstrated in animals for more than 6months. Nevertheless we concluded that we should focus at least initially on the therapy of acute conditions.


The synthetic biological components that needed to be developed

Universal orthogonal bistable toggle switch for mammalian cells

Figure 2. Regulation of the several different states of therapeutic cells based on several orthogonal toggle switches.
The existing genetic switches used in mammalian cells are mainly based on the available prokaryotic transcriptional regulators, whose number is currently limited and whose properties may differ, hindering balanced switching. Our idea was to investigate the development of orthogonal genetic switches based on designed DNA-binding domains, such as TAL effectors that could support simultaneous introduction of several toggle switches into mammalian cells. Although designed transcription factors have been created based on modular DNA binding proteins, such as zinc fingers and TAL effectors, to our best knowledge there have been no reports of genetic switches based on these types of elements. These devices would be extremely valuable since we could produce numerous orthogonal switches allowing development of complex control functions and therapeutic devices.




Safety mechanisms for therapy with microencapsulated cells

For the safe therapeutic implementation of microencapsulated engineered cells in the organism we envisioned that we should be able to cease the therapy without having to physically remove the capsules. We therefore designed safety mechanisms that allow a complete removal of all exogenous material after the therapy has been completed.

Figure 3. Safety mechanisms that we planned to introduce for the application of microencapsulated engineered mammalian cells in therapy.

Microcapsule degradation - Most of the microcapsules used in literature and therapy are composed of polymerized alginate that is biocompatible but cannot be degraded in mammalian tissues. Alginate lyase harvested from a marine microorganism effectively degrades alginate, so secretion of this enzyme from cells should degrade the capsules and allow their resorption by phagocytic cells.

Termination - We should be able to inactivate the implanted cells at the end of the therapy or at any other stage if the therapy has to be terminated, regardless of the cause. We introduced a safety mechanism that would enable controlled induction of apoptosis of the implanted cells that is leak-free until the selected moment. Therefore we could inactivate therapeutic cells and enable their resorption without causing inflammation.

Escape tag – This ensures that any cell that may have escaped from a microcapsule is eliminated by the immune system of the host organism. The escaped cells would most likely be recognized as foreign in any case but in order to provide maximal safety measures we decided to introduce an additional tag that would alert the natural killer cells of the host immune response.


Next: The switch >>